Because GLP-1 is rapidly degraded by the enzyme Di-Peptidyl Peptidase Type IV (DPP-4) and therefore has a very short plasma half-life, analogues of GLP-1 that are more resistant to DPP-4 degradation or DPP-4 inhibitors are currently used to treat T2DM [5]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.